Stockscreener 앱 받기
0.00
100.00%
-9.50
전일 마감가:
$9.50
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$925.93M
수익:
$64.70M
순이익/손실:
$-123.43M
주가수익비율:
0.00
EPS:
-1.38
순현금흐름:
$-95.23M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$9.67
포세이다 테라퓨틱스 Stock (PSTX) Company Profile
명칭
Poseida Therapeutics Inc
전화
858-779-3100
주소
9390 TOWNE CENTRE DRIVE, SAN DIEGO
PSTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSTX
Poseida Therapeutics Inc
|
0.00 | 925.93M | 64.70M | -123.43M | -95.23M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.68 | 113.49B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
686.33 | 75.42B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
648.11 | 39.38B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
279.19 | 36.01B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
124.30 | 29.80B | 3.30B | -501.07M | 1.03B | -2.1146 |
포세이다 테라퓨틱스 Stock (PSTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-04 | 개시 | H.C. Wainwright | Buy |
| 2022-01-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2020-08-04 | 개시 | BofA Securities | Buy |
| 2020-08-04 | 개시 | Piper Sandler | Overweight |
| 2020-08-04 | 개시 | William Blair | Outperform |
모두보기
포세이다 테라퓨틱스 주식(PSTX)의 최신 뉴스
Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida - MSN
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Barclays PLC - Defense World
Roche to close $1.5B acquisition of Poseida Therapeutics - MSN
Jane Street Group LLC Has $296,000 Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics Completes Merger with Roche Holdings, Inc. and Blue Giant Acquisition Corp. - Defense World
Poseida Therapeutics acquired by Roche Holdings - Investing.com Australia
Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win (RHHBY) - Seeking Alpha
Major pharmaceutical company Roche buys cell and gene developer Poseida Therapeutics in $1.5 billion acquisition - BioProcess Insider
Poseida Therapeutics acquired by Roche Holdings By Investing.com - Investing.com South Africa
Roche completes tender offer for Poseida Therapeutics shares By Investing.com - Investing.com Canada
Roche Completes Biopharma Acquisition Worth Up To $1.5B - Law360
Poseida Therapeutics Undergoes Merger and Delisting Changes - TipRanks
Roche set to finalise $1.5bn Poseida Therapeutics takeover - Proactive Investors USA
Roche Finalizes Tender Offer for $1.5B Poseida Deal - TipRanks
Roche: Poseida acquisition nears completion -January 08, 2025 at 04:55 am EST - Marketscreener.com
Roche completes tender offer for Poseida Therapeutics shares - Investing.com India
Roche Completes Acquisition of Poseida TherapeuticsNews and Statistics - IndexBox, Inc.
Roche to close $1.5B acquisition of Poseida Therapeutics (OTCQX:RHHBY) - Seeking Alpha
Roche to complete acquisition of U.S. biopharma company Poseida - MSN
Roche to complete acquisition of U.S. biopharma company Poseida -January 08, 2025 at 01:35 am EST - Marketscreener.com
Roche purchases shares in tender offer for Poseida Therapeutics, Inc. - The Manila Times
Roche Completes Major Acquisition of Poseida Therapeutics with 66% Share Tender Success - StockTitan
Poseida Therapeutics (NASDAQ:PSTX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Poseida announces US waiting period expiration for deal with Roche - MLex
Geode Capital Management LLC Sells 5,438 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Bought by Barclays PLC - MarketBeat
Poseida Therapeutics (NASDAQ:PSTX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Poseida Therapeutics stock soars to 52-week high of $9.59 By Investing.com - Investing.com Australia
Poseida Therapeutics (NASDAQ:PSTX) Sets New 1-Year HighHere's Why - MarketBeat
Poseida Therapeutics stock soars to 52-week high of $9.59 - Investing.com
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Wellington Management Group LLP Reduces Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics (NASDAQ:PSTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Charles Schwab Investment Management Inc. Increases Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? - MSN
XTX Topco Ltd Increases Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics executive chairman sells $283,866 in stock By Investing.com - Investing.com Canada
Poseida Therapeutics executive chairman sells $283,866 in stock - Investing.com
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - The Eastern Progress Online
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - The Eastern Progress Online
Poseida Therapeutics' SWOT analysis: gene therapy firm's stock shows promise amid challenges - Investing.com Nigeria
Poseida Therapeutics' SWOT analysis: gene therapy firm's stock shows promise amid challenges By Investing.com - Investing.com South Africa
포세이다 테라퓨틱스 (PSTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.35%
0.09%
자본화:
|
볼륨(24시간):